Literature DB >> 2227120

Defective free-fatty acid and oxidative glucose metabolism in IDDM during hypoglycemia. Influence of glycemic control.

S Caprio1, S Amiel, W V Tamborlane, R A Gelfand, R S Sherwin.   

Abstract

To examine the impact of diabetes and its treatment on plasma free-fatty acid (FFA) and oxidative fuel metabolism during hypoglycemia, we combined indirect calorimetry with [3-3H]glucose during a 4-h low-dose insulin infusion (plasma insulin approximately 2-fold above basal) in six poorly controlled and nine well-controlled insulin-dependent diabetes mellitus (IDDM) patients and in six healthy subjects. Diabetic subjects received insulin overnight to maintain euglycemia before study. Although free-insulin levels and counterregulatory hormone responses were similar, the plasma glucose fall was more pronounced in well-controlled diabetic subjects. In well-controlled diabetic and healthy subjects, the small increment in insulin rapidly suppressed plasma FFA and fat oxidation by approximately 50% and stimulated carbohydrate oxidation by approximately 80%. In contrast, plasma FFA levels did not fall in poorly controlled diabetic subjects, and glucose oxidation was not stimulated. To determine whether this resistance to the antilipolytic effect of insulin occurs in the absence of hypoglycemic counterregulation, we used a sequential low-dose euglycemic insulin clamp (0.2, 0.3, and 0.5 mU.kg-1.min-1). In healthy subjects, plasma FFA was nearly maximally suppressed at the lowest insulin dose. In contrast, plasma FFA remained persistently elevated in poorly controlled diabetic subjects at each insulin dose. However, the insulin dose-response curve for suppression of plasma FFA was near normal in well-controlled subjects. We conclude that poorly controlled IDDM diabetic patients are resistant to the antilipolytic effects of insulin and show impaired stimulation of glucose oxidation during insulin-induced hypoglycemia. Amelioration of these defects in well-controlled patients may be another factor contributing to the higher risk of hypoglycemia during intensified insulin therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227120     DOI: 10.2337/diab.39.2.134

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis.

Authors:  C G Fanelli; P De Feo; F Porcellati; G Perriello; E Torlone; F Santeusanio; P Brunetti; G B Bolli
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

2.  Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus.

Authors:  H Shamoon; S Friedman; C Canton; L Zacharowicz; M Hu; L Rossetti
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 3.  Mechanisms modifying glucose oxidation in diabetes mellitus.

Authors:  P J Randle; D A Priestman; S Mistry; A Halsall
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

4.  Hypoglycemia following pancreas transplantation.

Authors:  Joy Shen; Jason Gaglia
Journal:  Curr Diab Rep       Date:  2008-08       Impact factor: 4.810

5.  Inhibition of muscle glycogen synthase activity and non-oxidative glucose disposal during hypoglycaemia in normal man.

Authors:  L Orskov; J F Bak; O Schmitz; F Andreasen; E A Richter; C Skjaerbaek; N Møller
Journal:  Diabetologia       Date:  1996-02       Impact factor: 10.122

6.  Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles.

Authors:  Yuji Kawaguchi; Jun Sawa; Noriko Sakuma; Yasuro Kumeda
Journal:  J Diabetes Investig       Date:  2018-07-28       Impact factor: 4.232

Review 7.  Mechanisms of the Regulation and Dysregulation of Glucagon Secretion.

Authors:  Arnold N Onyango
Journal:  Oxid Med Cell Longev       Date:  2020-07-21       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.